Dr. James Stark presented the following article at Journal Club this week:

Daclizumab in Active Relapsing Multiple Sclerosis (CHOICE study): A phase 2, randomized, double-blind, placebo-controlled, add-on trial with IFN-beta.

The article presents the results of the phase 2 daclizumab therapy trial. Daclizumab is a monoclonal antibody against a specific part of an immune cell. It is administered by subcutaneous injection once a month. The results showed that patients treated with daclizumab and Avonex had fewer active MRI lesions than patients treated with Avonex alone. The number of patients and the duration of treatment were very small, however. A large, phase 3 study is currently underway and the IMSMP is planning on participating.